

Maxolon-controlling heartburn by tightening the sphincter.

Prescribing Information

Indications

Heartburn, dyspepsia and flatulence associated with the following conditions e.g. Reflux oesophagitis, Gastritis, Hiatus hernia, Peptic ulcer. Nausea and vomiting associated with e.g. Gastro-intestinal disorders.

Adult dosage (Oral, IM or IV)

Total daily dosage of Maxolon, especially for children and young adults should not normally exceed 0.5 mg/kg body weight. Adults: 10 mg three times daily

Young Adults (15-20 years): 5-10 mg three times daily, commencing at the lower dosage For dosage in children, please consult Data Shoot

Side effects and precautions

There are no absolute contra-indications to the use of Maxolon.

If vomiting persists the patient should be re-assessed to exclude the possibility of an underlying disorder, e.g. cerebral irritation.

Various extra-pyramidal reactions to Maxolon, usually of the dystonic type, have been reported. The incidence of these reactions in children and young adults may be increased if daily dosages higher than 0.5, mg/kg body weight are administered.

The majority of reactions occur within 36 hours of starting treatment and the effects usually disappear within 24 hours of withdrawal of the drug. Should treatment of a reaction be required, an anticholinergic anti-Parkinsonian drug, or a benzodiazepine may be used. Since extra-pyramidal symptoms may occur with both Maxolon and

phenothiazines, care should be exercised in the event of both drugs being prescribed concurrently.

Raised serum prolactin levels have been observed during metoclopramide therapy: this effect is similar to that noted with many other compounds.

Maxolon's action on the gastro-intestinal tract is antagonised by anticholinergics. Although animal tests in several mammalian species have shown no teratogenic effects. treatment with Maxolon

is not advised during the first trimester of pregnancy.

Following operations such as pyloroplasty or gut anastomosis Maxolon therapy should be withheld for three or four days since vigorous muscular contractions may not help healing. Availability and NHS prices

Tablets 10 mg (£9.78 for 100). Syrup 5 mg/5 ml (£3.36 for 200 ml). Ampoules for injection 10 mg (£2.69 for 10). Paediatric Liquid 1 mg/1 ml (£1.52 for 15 ml). Prices correct at August 1982.




Further information is available on request to the company

Beecham Research Laboratories

Brentford, England PL 0038/0095 0098 5040 5041. Maxolon and the BRL logo are trade marks

References: 1. Br Med J (1979) 1: 3-4, 2. Gut (1973) 14: 275-279, 3. Gut (1973) 14: 380-382, 4. Gastroenterology (1975) 68 (5): 1114-1118, 5. Gastroenterology (1976) 70 (4): 484-487, 6. Anaesth Intens Care (1978) 6 (1): 26-29, 7. Gastroenterology (1980) 78 (5) pt 2: 1292, 8. Tijdschr Gastro-Enterol (1977) 20 (3): 155-162, 9. Dt Z Verdau-u-Stoffwechselkr (1981) 41: 13-17, 10. Postgrad Med J (July Suppl. 1973) 104-106, 11. Z Gesund Inn Med. (1981): 122-124.



Is most of the data you record following an endoscopy consigned to oblivion? Or despatched with the patient? Or lost in another department? Using PEDRO as an integral part of your post-endoscopy routine will retain

full details for your own later use as well as providing hard copy for patients' notes and other interested parties. PEDRO'S total recall allows you to easily search for cases of interest, histological correlations and developing trends, and to improve management by recalling patients for follow-up, listing biopsy results and producing standard house-keeping audit figures. IT'S SAFE AND EASY TO USE.

IIIII PEDRO

- ★ No computer knowledge required no keytopard codes.
- ★ Rapid data entry and short learning time (30 minutes)
- ★ Flexible and comprehensive the data base is as simple: as detailed as you wish to make it.
- Offers many features for analysis of clinical data and improvements in patient management.
- ★ Simplifies audit justification for increased staffing and replacement of equipment.
- ★ Program design facilitates future expansion and enhancements.

Choosing a computer system is a long term investment – invest in the future with KeyMed – the company with a proven customer service record.

PATIENT ENDOSCOPY DATA & RECORDS ORGANISER

KEY MED

Specialised Services to Medicine KeyMed House, Stock Road Southend-on-Sea, Essex SS2 5QH, England.Tel:(0702) 616333 (20 lines) Telex: 995283 Telefax: (0702) 65677

COLPERMIN

(enteric-coated peppermint oil)

An exclusive two-dimensional remedy for irritable bowel syndrome

Prescribing Information

Presentation: A light blue/dark blue enteric-coated hard gelatin capsule size 1, with a green band between cap and body. Each capsule contains 0.2 ml standardised peppermint oil B.P., Ph. Eur. Uses: For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. The enteric-coating of the capsule delays release of the peppermint oil until it reaches the distal small bowel. The oil exerts a local effect of colonic relaxation and a fall of intracolonic pressure.

Dosage and Administration: For oral administration. Adult dose: One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should <u>not</u> be taken immediately after food. The dose may be increased to two capsules. three times a day when discomfort is more severe. The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15

years.

Contraindications, Warnings, etc. Precautions: The capsules should not be broken or chewed because this would release the peppermint oil prematurely, possibly causing local irritation of the mouth and oesophagus. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule. Treatment should be discontinued in these patients.

Adverse effects: Heartburn; sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. Treatment of overdosage: If capsules have been recently ingested, the stomach should be emptied by gastric lavage. Observation should be carried out with symptomatic treatment if necessary.

Pharmaceutical Precautions: Store in a cool place. Avoid direct sunlight.

Legal category: P.

Package quantity: Containers of 100 capsules.

Further information: Nil.

Product Licence: PL 0424/0009. Basic NHS cost: £10.00 per 100.

European Patent No. 0015334 U.K. Patent No. 2 005 011 Colpermin is a trade mark of Tillotts Laboratories


REFERENCE:

1. Rees WDW. Evans BK. Rhodes J: Treating irritable bowel syndrome with peppermint oil. Br Med J 2:835-836, 1979.



2-7126







Proven effective over seven years of widespread clinical experience. Tagamet' is a known quantity in peptic ulcer treatment.

With 'Tagamet', 25 million patients ahead of the less experienced newcomers, you're on familiar ground.

Tagamet (C)

THOROUGHLY EXPLORED

Puts you in control of gastric acid

Prescribing Information

Prescribing Information
Presentations Tagainet Tablets, Pt. 0002: 0092; each containing 400 mg cimicidine - 86. £16.61. Tagainet Tablets, Pt. 0002: 0093; each containing 200 mg cimicidine - 86. £16.61. Tagainet Strup, Pt. 0002: 0073; containing 200 mg cimicidine per 5 ml. 200 ml. £8.17 Indications. Dioidenal ufcer beingin quastric ufcer recurrent and stomal ufceration, oesephapea; incline stosease. Other conditions where reduction of gastric acid is beneficial prophylaxis of stress-induced gastrointestinal haemorrhage, and of acid aspiration (Mendelsons) syndrome. An additional malabsoription and fluid loss in short bowel syndrome. Zollinger-Ellison syndrome. Dosage Usual dosage: Adults: Duodenal ufcer. 400 mg b d with breaktast and at bedtime or 200 mg if a s with meals and 400 mg at bedtime (1.0.g. day) for at least 4 weeks. To prevent relapse. 400 mg at

bedtime or 400 mg morning and at bedtime for at least 6 months. Benign gastric ulcer, 200 mg t d s. with meals and 400 mg at bedtime (1.0 g day) for at least 6 weeks. Oesophageal reflux disease, 400 mg t d s. with meals to at least of wear Sesophiager Final vineate. Soon got 0.3 min feat and 400 mg at bedtime (1.6.g. day) for 4 to 8 weeks. Prophylaxis of stress-induced gastrointestinal haemorrhage. up to 2.g. a day, divided, to maintain intragastric pH above 4. Prophylaxis of acid aspiration syndrome, 400 mg 90-120 mins before induction of general anaesthesia 400 mg at start of labour then 200 mg 2-hourly as necessary, maximum 1.6 g. Do not use Tagamet syrup. Zollinger-Ellison syndrome, up to 400 mg q i.d., rarely up to 2 g a day. Recurrent and stomal ulceration and

SKSF SMITH KLINE & FRENCH LABORATORIES LIMITED. Welwyn Garden City, Hertfordshire AL7 1EY c 1983 Smith Kline & French Laboratories Limited Tagamet is a trade mark TG:AD194

wel syndrome, 200 mg t.d.s. and 400 mg at bedtime (1 0 g/day) NB For full dosage instructions see Data Sheet. Cautions Impaired renal function reduce dosage (see Data Sheet). Potentiation of oral anticoagulants, phenytoin and theophylline (see Data Sheet). Prolonged treatment observe patients periodically Exclude malignancy in gastric ulcer Care in patients with compromised bone marrow (see Data Sheet). Avoid during pregnancy and lactation. Adverse reactions Diarrhoea.

THE BEST CHOICE EVERY TIME

IT WORKS In the treatment of ulcerative colitis, Colifoam is as effective as steroid enemas. At the same time it has been shown that patients find the foam easier to retain.^{1, 2}

PATIENTS PREFER IT

Colifoam is far more comfortable, more convenient and more acceptable than enemas. Patients also find it easier to administer and that it causes less interference in their daily lives.

IT COSTS LESS

Surprisingly, despite the fact that it's just as effective and far more comfortable, Colifoam is less expensive. In fact, it can cost up to ½ less per dose than a standard proprietary enema.

T'S SAFER

ent clinical data shows Colifoam has aremely low levels of systemic absorption,4 wer than proprietary prednisolone enemas.5 herefore, there is less potential for adrenal uppression which means that Colifoam hay be considered safer in long-term

COLIFOAM

In although the men and forest

IN DISTAL INFLAMMATORY BOWEL DISEASE. THE BEST CHOICE EVERY TIME

Presentation White odourless aerosol foam containing hydrocortisone acetate PhEur 10%. Uses Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with every pack). Satisfactory response usually occurs within five to seven days. Contra-indications, warnings etc. Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fixtuale. General precautions common all corticosteroid therapy should be observed during reatment with Coliforam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refiregierate. Shake vigorously before use. Keep out of reach of children. For external use only. Legal category POM. Package quantities Aerosol canister containing 25g (approx. 14 applications). Basic NHS cost 25g plus applicator, £7.40. Further Information One applicatorful of Coliforam provides a dose of approximately 125m gof hydrocortisone accetae, similar to that used in a retention enema, of the treatment of ulcerative colificia, signoiditis and proctitis. Product Licence No. 0036/0021. References L Ruddell WSJ, et al. Gut 1980; 21: 857–850. Source: Mins. 4. Barr WH, Kline B, Beighot L. Zfass A, Medical College of Virginia Commonwealth University, FDA bioavailability submission document October 1981. 5. Lee DAH, et al. Gut 1980; 21: 515–218. Further information is available on request. Stafford-Miller Ltd.

Professional Rel


Gastrozepin is a selective antimuscarinic agent which provides balanced control of gastric secretion without markedly affecting other peripheral receptor sites. This gastro-selective action means that, in practice, Gastrozepin is a well-tolerated drug which heals peptic ulcers.

Gastrozepin DOES NOT . . .

- rely on acid reduction alone
- rely on pepsin reduction alone
- rely on mucosal protection alone
- profoundly affect intragastric pH


Gastrozepin DOES . . .

- relieve daytime pain
- relieve night-time pain
- reduce antacid intake
- heal peptic ulcers with one 50 mg tablet b.d.



Prescribing Information: Presentation: White tablets each containing 50 mg of pirenzepine dhydrochloride scored on one face with "G" on one side of the score; and "50" on the other The obverse is impressed with the symbol **@** Uses: Gastrozepins, indicated in the treatment of gastric and duodenal ulicen; **Dosage**: 50 mg at bettime and in the morning before meals in severe cases the total daily does may be increased to 150 mg in divided doses. Continuous therapy may be recommended for up to three months. **Contra-indications, Warnings etc.** interaction with sympathomimetrics and monoamme coxidase inhibitors and Gastrozepin is a theoretical possibility. Gastrozepin is not recommended during pregnancy although in animal

experiments no teratogenic effects were noted. Breast milk concentration after therapeutic doses is unlikely to affect the infant. Side effects occasionally transitory dry mouth and accommodation difficulty may occur Treatment of overdosage entirely symptomatic. There is no specific antidote Basic NHS price: 50 mg tablets, 60 £20 50. Product Licence No.: 50 mg tablets, 120.014.0260



Have you the the abilities?




- Viewability
- Cleanability
- Immersibility
- Durability
- Serviceability
- Interchangeability


Only the Olympus Endoscopy System with a range of flexible endoscopes for oesophagoscopy, gastroscopy, duodenoscopy, sigmoidoscopy, colonoscopy and bronchoscopy, gives you more abilities – the abilities **you've asked for**.


Only the Olympus Endoscopy System is backed by KeyMed's unique 12-month entirely unconditional guarantee and commitment to customer service that is second to none.



The ultimate fiberscopes by **OLYMPUS** from KEY & MEL







Mary Committee of the C

ENGLISHED STATES





Specialised Services to Medicine KeyMed House, Stock Road Southend-on-Sea, Essex SS2 5QH, England.Tel:(0702) 616333 (20 lines) Telex: 995283 Telefax: (0702) 65677

Antepsin[®] Antepsin[®] Sucraifate Mucoprotective ulcerhealer

ealer Mucopro ...c: nealer Mucoprole-Mucoprotective he er healer Mucoprotective ulcer her Protective ulcer he healer Mucoprotective uice "UCOprotective ulcer healer Mucoprotective" Protective ulcer healer Mucoprotective ulcer have protective ulcer healer Mucoprotective ulcer have protective uker healer Mucoprotective uker healer healer Mucoprotective uker healer healer healer heal Her Mucoprotective ulcer healer Mucoprotective ulcer heale ducoprotective ulcer healer Mucoprotective ulcer healer Mu Mucoprotective ulcer healer Mu rotective ulcer healer Mucoprotective ulcer healer Mucopro sective ulcer healer Mucoprotective ulcer healer Mucoprote ulicer healer Mucoprotective ulcer healer ulcer healer Mucoprotective ulcer healer Mucoprotective ulcer healer ulcer healer ulcer healer healer Mucoprotective ulcer healer ulcer healer ulcer healer ulcer healer ulcer healer ul ealer Mucoprotective ulcer healer Mucoprotective ulcer hea Jective ulcer healer Mucoprotective ulcer healer Muc tive ulcer healer Mucoprotective ulcer healer Mucoprotecti

Non-systemic action

Fast pain relief Excellent healing rates Prolonged remission Low incidence of side effects

Prescribing Information

Presentation Antepsin Tablets 1 gram are white, oblong, biconvex, uncoated tablets scored and embossed 1239 on one side and Ayerst on the other. Each tablet contains 1 gram sucralfate. Uses For the treatment of duodenal ulcer, gastric ulcer and chronic gastritis. Dosage and Administration For oral administration. Adults — Usual dose 1 gram 4 times a day. Maximum daily dose 8 grams. Four to six weeks treatment is usually needed for ulcer healing but up to twelve weeks may be necessary

in resistant cases. Antacids may be used as required for relief of pain. **Contra-indications**, **Precautions**, **Warnings**, **etc.** *Contra-Indications* There are no known


Warnings, etc. Contra-Indications There are no known contra-indications. Precautions 1. Concomitant administration with some oral anti-infectives such as tetracyclines may interfere with absorption of the latter. 2. The product should only be used with caution in patients with renal dysfunction. 3. As with all medicines, Antepsin should not be used in early pregnancy unless considered essential. Side Effects A low incidence of mild side effects, e.g. constipation, has been reported.

Legal Category POM. Package Quantities Antepsin 1 gram – Securitainers of 100. Pharmaceutical Precautions No special requirements for storage are necessary. Product Licence Numbers Pl. No. 0607/0045 PA No. 149/4/2. Basic N.H.S. Price Average daily cost 50p.



® ANTEPSIN is a registered Trade Mark.

Further information is available on request to the Company.



ETHICON

ETHICON Ltd., P.O. Box 408, Bankhead Avenue, Edinburgh EH11 4HE, Scotland. *Trademark©ETHICON Ltd 1983

Product Licence Nos PL 0508/0011 (dyed) PL 0508/0012 (clear

DATA SHEET

PDS* (Polydioxanone) Sterilised Absorbable Synthetic Suture

Presentation

PDS (Polydioxanone) Monofilament Synthetic Absorbable Suture is prepared from the polyester poly (p-dioxanone). The empirical molecular formula of the polymer is (C₄H₆O₃)n. PDS (Polydioxanone) sutures are coloured by adding D & C violet No 2 during polymerisation. These sutures may also be manufactured undyed (clear).

PDS (Polydioxanone) sutures are relatively inert, non-antigenic, nonpyrogenic and elicit only a mild tissue reaction during absorption.

Action

Two important characteristics describe the in vivo behaviour of absorbable sutures. The first of these is tensile strength retention and the second absorption rate or loss of mass.

Data obtained from implantation studies in rats show that, at two weeks post implantation, approximately 70% of the suture strength is retained whilst at four weeks the strength retention is approximately 50%. At eight weeks approximately 14% of the original strength remains. This indicates a significantly longer period of wound support than previously available with an absorbable suture.

The absorption or loss of mass is minimal until about the 90th post implantation day and is essentially complete within six months.

Uses

PDS (Polydioxanone) monofilament sutures are intended for use where an absorbable suture or ligature is indicated. They may have particular application where longer wound support is required. See strength retention data above.

Dosage and Administration

By implantation

Contraindications, Warnings, etc.

These sutures, being absorbable, should not be used where extended approximation of tissues under stress is required.

As with all monofilament synthetic sutures, care should be taken to ensure proper knot security.

Conjunctival, cuticular and vaginal mucosal sutures could cause localised irritation if left in place for longer than 10 days and should be removed as indicated.

The safety and effectiveness of PDS (Polydioxanone) sutures in neural and cardiovascular tissue have not yet been established. The use of this material in the renal tract is currently under investigation.

Pharmaceutical Precautions

Do not resterilise.

Legal Category P

Pharmacy medicine sold to surgeons and hospitals through surgical dealers.

Package Quantities

The gauge range initially available will be 0.7 metric (6/0) to 4 metric (1). Various lengths of material attached to non traumatic stainless steel needles are packaged in sealed aluminium foil sachets.

This primary pack is contained in a peel-apart secondary pack. The unit of sale is 24 packs contained in a film wrapped drawer style carton.

Further Information

No suture related adverse reactions were reported during clinical trials, although a number of minor reactions were classified as being of unknown cause.

Product Licence Nos PL 0508/0011 (dyed) PL 0508/0012 (clear)

Br Pat No 1 540 053

ETHICON LTD. PO BOX 408, BANKHEAD AVENUE **EDINBURGH EH11 4HE**

A new diagnostic promise in gastroenterology



SeHCAT is a 8-labelled taurine conjugate of homocholic acid. It has been shown to mimic the reabsorption and enterohepatic circulation of the endogenous bile acid pool, and is particularly resistant to deconjugation by intestinal flora.

SeHCAT represents a significant breakthrough, enabling for the first time, accurate and convenient measurement of bile acid pool turnover and assessment of ileal reabsorptive function.

SeHCAT has four broad areas of application:

- Measuring ileal function following gastrointestinal surgery.
- Indicating the extent of ileal involvement in inflammatory bowel disease.
- Classification of patients suffering chronic diarrhoea.
- Research into the dynamics of the enterohepatic circulation.

Such enormous diagnostic promise has already produced some exciting results.

Information about the product, its applications and the results it has produced are available on request.

SeHCAT

The first accurate, convenient measure of bile acid pool turnover

Amersham International plc

Amersham England HP7 9LL telephone Little Chalfont (024 04) 4444





Mediaeval Crusades



Bodily defence still relies on shields



Era of Richard III

NOW! A natural mucosal shield helps heal peptic ulcers!

CAVED-So does what no other ulcer therapy can do: it increases the number of mucussecreting cells1 with virtually no side effects.2 This protects the gastric mucosal barrier against damaging agents 3, 4, 5 and reduces ulcer recurrence.6

An 88% healing rate in 12 weeks7 has been reported. Studies also confirm that CAVED-S offers comparable efficacy to cimetidine in healing gastric ulcers7 and comparable efficacy to ranitidine in healing duodenal ulcers.6

REFERENCES:

REFERENCES:

1. Van Marie J, Aarsen PN, Lind A, et al: Degly-cyrrhizinised liquorice [DGL] and the renewal of rat stomach epithelium. Eur J Pharmacol 72:219-225, 1981. 2. Cooke WM, Baron JH: Meta-bolic studies of deglycyrrhizinated liquorice in two patients with gastric uler. Digestion 4:264-268, 1971. 3. Rees WDW, Rhodes J, Wright IE, et al: Effect of deglycyrrhizinated liquorice on gastric mucosal damage by aspirin. Scand J Gas-troenterol 14:605-607, 1979. 4. Morgan RJ, Nel-son LM, Russell RI, et al: The effect of deglycyr-rhinized liquorite on a the occurrence of sapirin rhinized liquorite on the occurrence of sapirin and aspirin plus bile acid-induced gastric lesions, and aspirin absorption in rats, abstracted.



(deglycyrrhizinated liquorice alum hydrox gel, mag carb, sod bic)

"The Mucosal Shield" for peptic ulcers.



Henlow Trading Estate, Henlow, Bedfordshire. SG16 6DS. Telephone 0462 813933 Telex: 82313 Tillab G.

PRESCRIBING INFORMATION

Presentation Brown tablets embossed 'CAVED-S; each containing:
Deglycyrrhizinated Liquorice 380 mg
Dried Aluminum hydroxide gel 100 mg 380 mg 100 mg

Magnesium carbonate Sodium bicarbonate

For the treatment of peptic ulcer and other allied conditions. Dosege and Administration: Adult dose for gastric ulcer: 2 tablets 3 times a day between meals.

Adult dose for duodenal ulcer:
Increase to 2 tablets 6 times a day between meals when necessary.

Prophylactic dose:

Gastric ulcer:

I tablet 3 times a day, between meals Duodenal ulcer:

Children's dosage 10-14 years: half adult dose The tablets should be lightly chewed and swallowed with a drink of water,

but in exceptional case of objection to taste, the tablets should be broken into a few pieces and then swallowed with a drink of water. No additional antacids are necessary.

Contra-indications, warnings, etc.

Rare cases of mild diarrhoce can occur. No other side-effects have been reported.

Caved-S should be used with caution in pregnancy. Basic NHS Price: 60's—£2.83 240's—£10.12 600's—£22.76 PL0424/5000.



Gastroenterology 82:1134, 1982. 5. Morris TJ,
Calcraft BJ, Rhodes J, et al: Effect of a
deglycyrrhizinised liquorice compound in the
gastric mucosal barrier of the dog. Digestion
11:355-363, 1974. 6. McAdam WAP, Morgan KC,
Pasoo C, et al: A comparison between ramitidine
and Caved-5 in duodenal ulcer treatment,
abstracted. Proceedings, World Congress of
Gastroenterology, Stockholm, June 1982.
7. Morgan AG, McAdam WAP, Pascoo C:
Comparison between cimetidine and Caved-5 in
the treatment of gastric ulceration, and the treatment of gastric ulceration, and subsequent maintenance therapy. Gut

The liquid life-line





for the medical patient

Administration of Fortison feeding is most easily accomplished using the Fortison feeding set (gastric drip line) and the Fortison tube.

For further information contact—
Cow & Gate Limited, Clinical Products Division,
Cow & Gate House, Trowbridge, Wiltshire, BA14 8YX.
Telephone: Trowbridge 02214 68381.



XVIII Gut March 1984

ABC OF COMPUTING


Although computers are being widely used in medicine, their possibilities and limitations are still not clear to many potential users. This book, aimed at the non-expert, describes some of the uses of computers in medicine; because most doctors' involvement will be indirect, liaising with computer experts rather than designing systems themselves, the book concentrates on concepts rather than detailed descriptions of how computers work. It provides a useful introduction for the doctor who wants

to know how computers can contribute to his practice of medicine.

Price: Inland £5.75; Overseas £8.00*/USA \$14.00* (Inland £5.25; Overseas £7.50*/USA \$13.00* to BMA members) *including air mail postage

Payment must be enclosed with order

Order your copy now From: The Publisher British Medical Journal, BMA House, Tavistock Square, London WC1H 9JR or any leading bookseller



CONTENTS

VOLUME 19, NO. 1, JANUARY 1984

SCANDINAVIAN JOURNAL OF Gastroenterology

Review: Mass Screening for Colorectal Cancer	O. Kronborg	1
Incorporation of Precursors into Sterols and Proteins in Liver Biopsies from Patients with Liver Disorders	S. A. Evensen, S. Ritland, K. Elgjo, H. E. Solberg & S. Skrede	6
Intragastric Bacteria and Nitrite after Short-Term Treatment with Different Doses of Antimuscarinic Drugs	R. W. Stockbruegger, S. Seeberg, L. Hellner, B. H. Jaup & G. Dotevall	14
The Effect of Graded Doses of Secretin on Serum Trypsin, Serum Pancreatic Amylase, Serum Insulin, Plasma Somatostatin, and Plasma Pancreatic Polypeptide in Man	J. Florholmen, P. G. Burhol, R. Jorde & H. L. Waldum	24
Acute Gastritis Clinically Classified in Accordance with Data from Both Upper GI Series and Endoscopy	K. Sugimachi, K. Inokuchi, H. Kuwano & T. Ooiwa	31
Serum Ferritin in Acute Viral Hepatitis	N. Milman & N. Graudal	38
Are All Gliadins Toxic in Coeliac Disease? An in Vitro Study of α , β , γ , and w Gliadins	P. D. Howdle, P. J. Ciclitira, F. G. Simpson & M. S. Losowsky	41
Effect of Intravenous and Intrajejunal Fat Infusion on Gastric Acid Secretion and Plasma Neurotensin-like Immunoreactivity in Man	B. Petersen, J. Christiansen, Å. Rökaeus & S. Rosell	48
Serum Group I Pepsinogens after Consecutive Stimulations with Insulin and Pentagastrin in Unoperated Duodenal Ulcer Patients and in Duodenal Ulcer Patients after Proximal Gastric Vagotomy	H. Paimela, M. Lalla & V. Räsänen	52
Additional Antacid Does Not Increase the Effect of Cimetidin in Gastric Ulcer Disease	S. J. Rune, K. J. Jensen, H. R. Wulff, F. Bendtsen, J. Lindskov, J. Mejer, M. Højlund, V. R. Nissen, L. Willumsen, E. Agner, L. Tougaard, E. Kristensen, & KM. Møllmann	56
Responses of Vasoactive Intestinal Polypeptide, Secretin, and Human Pancreatic Polypeptide to Glucose during Fasting	O. Øktedalen, P. K. Opstad, R. Jorde & O. B. Schaffalitzky de Muckadell	59
Intraoperative pH of the Gastric Mucosa before and after Truncal Vagotomy in the Dog: The Grassi Test	J. O. Larsson	65
Effect of Duodenal Feeding on Serum Gastrin and Acid Response to Pentagastrin in Cats	M. Fernström, G. Nilsson & S. Emås	71
Plasma Alpha-Lipoprotein Pattern and LCAT Activity in Acute Viral Hepatitis in Children	A. Avgerinos, N. Thalassinos, P. Skliros, A. Yalouris, J. Vrettos & G. Arapakis	76
IgA Antibodies to Herpes Simplex Virus Type 1 in Duodenal Juice and Saliva from Patients with Peptic Ulcer and Non-Ulcer Controls	S. J. Rune & B. F. Vestergaard	81
Gastro-Oesophageal Reflux in Pregnancy. Altered Function of the Barrier to Reflux in Asymptomatic Women during Early Pregnancy	E. T. Bainbridge, S. D. Nicholas, J. R. Newton & J. G. Temple	85
Prediction of Fatality in Fulminant Hepatic Failure	E. Christensen, A. Bremmelgaard, M. Bahnsen, P. Buch Andreasen & N. Tygstrup	90
Evidence of Increased Intestinal Synthesis and Extracellular Deposition of IgM in Primary Biliary Cirrhosis. An Immunofluorescence Study of Liver and Small-Intestinal Biopsy Specimens	S. Lindgren, J. McKay, I. Hansson & S. Eriksson	97
Bacterial Colonization and Nitrite Concentrations in the Achlorhydric Stomachs of Patients with Primary Hypogammaglobulinaemia or Classical Pernicious Anaemia	J. M. Dolby, A. D. B. Webster, S. P. Borriello, F. E. Barclay, B. A. Bartholomew & M. J. Hill	105
Tinidazole Prophylaxis in Appendicectomies. A Controlled Study of Single- Dose versus 3-Day Therapy	J. Vitanen, T. Tunturi, O. Auvinen & T. Pessi	111
Conjugated Bile Salts in Gastric Aspirates after Gastric Resection	H. Graffner, CH. Florén & Å. Nilsson	116
Treatment of Gastric Ulcer with Ranitidine	T. B. Schulz, A. Berstad, A. Rydning & K. Frislid	119
Studies of the Effect of Cerulein Administration on Experimental Pancreatic Carcinogenesis	Å. Andrén-Sandberg, S. Dawiskiba & I. Ihse	122

Abstracted in Excerpta Medica Indexed in Current Contents and Index Medicus

ISSN 0036-5521

Just published

AVIATION MEDICINE


This authoritative and highly readable account of the little known speciality of aviation medicine will interest both general readers and those interested in it as a career. Comprehensive information on the management of airline passengers with particular medical conditions before, during, and after flight will help doctors faced with deciding whether or not their patient is fit to fly and with coping with a medical emergency in the air while themselves passengers on board an aircraft. The chapters on the problems of altitude, acceleration, the function of the special senses in flight, special forms of flight, and aviation psychology describe clearly and precisely the physiological and

behavioural effects that flight imposes on man.

Price: Inland £5.50; Overseas £7.50*/USA \$13.00* (Inland £5.00; Overseas £7.00*/USA \$12.00* to BMA members) * including air mail postage

Payment must be enclosed with order

Order your copy now From: The Publisher, British Medical Journal, BMA House, Tavistock Square, London WC1H 9JR, or any leading bookseller



BUTTERWORTHS BOOKS FOR GASTROENTEROLOGISTS

Radiology in Inflammatory Bowel Disease

Clive I Bartram, MBBS, MRCP, FRCR

with contributions by

James P S Thomson, MS, FRCS and Ashley B Price, BM, BCh, MRC Path

An invaluable addition to the specialities of both radiology and gastroenterology, this book gives a full account of the radiological findings in inflammatory bowel disease. The very latest information is presented here in an easily accessible format, fully illustrated and complete with surgical and pathological correlations.

November 1983

328 pages

0 407 00329 0

Hardcover

Illustrated

£45.00

Butterworths International Medical Reviews – Gastroenterology Volume 4 – The Liver

Editors: Roger Williams, MD, FRCP Willis C Maddrev. MD

BIMR Gastroenterology 4 – The Liver is the fourth volume in a successful and informative series which will build to provide a complete practical account of contemporary gastroenterology.

December 1983

368 pages

0 407 02290 2

Hardcover

Illustrated

£38.00

Atlas of Colorectal Tumours

Professor Dr. Paul Hermanek, Professor Dr. Karl Karrer and Professor Leslie H Sobin

Over 300 illustrations, of which 70 are reproduced in full colour, complement an authoritative text to make this atlas an essential and attractive volume for all gastroenterologists.

January 1984

.148 pages

0 407 00340 1

Hardcover

Illustrated

£35.00

Liver Surgery

Editors: Professor Roy Y Calne, MD, FRS
G Querci della Rovere, MD, FRCS

'A richly illustrated anthology of liver surgery'

The editors have co-ordinated an international team of experts to survey all the major aspects of liver surgery. The authors of individual chapters draw upon their specialised knowledge of each operation to produce the most comprehensive and authoritative volume on liver surgery available today.

1982

258 pages

88 212 07439

Hardcover

Illustrated

£65.00

A Piccin Publication – distributed by Butterworths

For a leaflet giving full details of these titles please write to



Butterworths

BOROUGH GREEN, SEVENOAKS, KENT TN15 8PH